Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
A popular asthma inhaler is being discontinued. Although there is a generic version, the switch could lead to disruptions in care because not all insurance companies are covering it.
-
The National Institutes of Health has been reluctant to use its leverage as a biomedical research funder to influence drug pricing. Sen. Bernie Sanders is pressing NIH's new director to take action.
-
The Food and Drug Administration has approved approve the first RSV vaccine that can be given during pregnancy to protect newborn babies.
-
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now some copycats could end Humira's reign.
-
Here's what really went down when the FDA originally approved mifepristone in 2000.
-
There's a nationwide shortage of the antibiotic amoxicillin. It is making it harder for doctors to treat strep throat.
-
In a long anticipated decision, the Food and Drug Administration approved an over-the-counter version of naloxone spray, a generic form of the opioid overdose treatment called Narcan.
-
The U.S. Food and Drug Administration late last year got more leverage over pharmaceutical companies that received accelerated approvals for their drugs. How will the agency use its new powers?
-
The FDA announced the supply troubles in the fall. Four months later, the medication remains hard to get and could stay that way until the spring
-
The cost of prescription drugs have been a political issue for years. If Congress passes the Reduce Inflation Act, a provision would allow Medicare, for the first time, to negotiate drug prices.